Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study

Alzheimer Disease and Associated Disorders

Volumn 31, Issue 2, 2017, Pages 107-113

  Koenig, Aaron M ^a,c   Mechanic Hamilton, Dawn ^a   Xie, Sharon X ^b   Combs, Martha F ^a   Cappola, Anne R ^b   Xie, Long ^b   Detre, John A ^b   Wolk, David A ^a,b   Arnold, Steven E ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer disease; Arterial Spin Label (ASL) MRI; cerebrospinal fluid; insulin resistance; metformin; mild cognitive impairment (MCI)

Indexed keywords

BIOLOGICAL MARKER; LACTIC ACID; METFORMIN; PLACEBO; ANTIDIABETIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTERIAL SPIN LABELING; ARTICLE; ATTENTION; BODY MASS; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LEARNING; MEMORY; MILD COGNITIVE IMPAIRMENT; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; FEMALE; MALE; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; STATISTICS AND NUMERICAL DATA;

AGED; ALZHEIMER DISEASE; COGNITIVE DYSFUNCTION; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; NEUROPSYCHOLOGICAL TESTS;

EID: 85019626874     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000202     Document Type: Article

References (41)

1. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67:505-512.
2. Baker LD, Cross DJ, Minoshima S, et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68:51-57.
3. Correia SC, Santos RX, Perry G, et al. Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev. 2011;10:264-273.
4. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis. 2005;7:63-80.
5. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69:29-38.
6. Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res. 2011;8:592-606.
7. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30:131-146.
8. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol. 2003;162:313-319.
9. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005;26(suppl 1):65-69.
10. Baker LD, Cross DJ, Minoshima S, et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2010;68:51-57.
11. Craft S, Asthana S, Cook DG, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 2003;28:809-822.
12. Watson GS, Bernhardt T, Reger MA, et al. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging. 2006;27:38-41.
13. Dhamoon MS, Noble JM, Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2009;72:292-293. Author reply 293-294.
14. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69:29-38.
15. Morris JK, Vidoni ED, Mahnken JD, et al. Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin. Neurobiol Aging. 2016;39:19-24.
16. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology. 2011;60:910-920.
17. Berkowitz SA, Krumme AA, Avorn J, et al. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA Intern Med. 2014;174:1955-1962.
18. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. 2009;296:E581-E591.
19. Salminen A, Kaarniranta K, Haapasalo A, et al. AMPactivated protein kinase: a potential player in Alzheimer's disease. J Neurochem. 2011;118:460-474.
20. Labuzek K, Suchy D, Gabryel B, et al. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep. 2010;62:956-965.
21. Hsu CC, Wahlqvist ML, Lee MS, et al. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011;24: 485-493.
22. Kickstein E, Krauss S, Thornhill P, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A. 2010;107: 21830-21835.
23. Chen Y, Zhou K, Wang R, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A. 2009;106:3907-3912.
24. Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology. 1997;49:1096-1105.
25. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9(suppl 1):173-176. Discussion 177-178.
26. Engelborghs S, De Vreese K, Van de Casteele T, et al. Diagnostic performance of a CSF-biomarker panel in autopsyconfirmed dementia. Neurobiol Aging. 2008;29:1143-1159.
27. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65: 403-413.
28. Chen Y, Wang DJ, Detre JA. Test-retest reliability of arterial spin labeling with common labeling strategies. J Magn Reson Imaging. 2011;33:940-949.
29. Xie L, Dolui S, Das SR, et al. A brain stress test: Cerebral perfusion during memory encoding in mild cognitive impairment. Neuroimage Clin. 2016;11:388-397.
30. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI singlesubject brain. NeuroImage. 2002;15:273-289.
31. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
32. Egerhazi A, Berecz R, Bartok E, et al. Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:746-751.
33. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37-49.
34. Clark CM, Ewbank DC. Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord. 1996;10:31-39.
35. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
36. Bender R, Lange S. Adjusting for multiple testing-when and how? J Clin Epidemiol. 2001;54:343-349.
37. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44:83-98.
38. Frey S, Petrides M. Orbitofrontal cortex: a key prefrontal region for encoding information. Proc Natl Acad Sci USA. 2000;97:8723-8727.
39. Dai W, Lopez OL, Carmichael OT, et al. Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology. 2009;250:856-866.
40. Greenberg BD, Carrillo MC, Ryan JM, et al. Improving Alzheimer's disease phase II clinical trials. Alzheimers Dement. 2013;9:39-49.
41. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:1-7.